🇺🇸 FDA

Intelligence Platform

Patents

Browse 263 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11896672

Targeted nucleic acid conjugate compositions

ARBUTUS BIOPHARMA CORPORATION · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851671

Programmable assembly of virus composites for receptor-targeted gene delivery

Regents of the University of Minnesota · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814624

Targeted non-viral DNA insertions

The Regents of the University of California · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806432

Compositions, methods and uses for thermally stable multi-targeted antigens

The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786479

Nucleic acid nanocapsules for drug delivery and targeted gene knockdown

UNIVERSITY OF CONNECTICUT · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787778

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Montelino Therapeutics Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11780931

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11766403

Peptide-targeted liposomal delivery for treatment, diagnosis, and imaging of diseases and

United States Government as represented by the Department of Veterans Affairs · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723922

CXCR6-transduced T cells for targeted tumor therapy

Ludwig-Maximilians-Universitat Munchen · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11691972

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11684638

Targeted delivery system, system components, and methods

Regents of the University of Minnesota · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666661

Methods and compounds for targeted autophagy

The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661441

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649468

Targeted integration into the PPP1R12C locus

Sangamo Therapeutics, Inc. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642319

Targeted nanogels for urinary bladder therapies

The Regents of the University of Colorado · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596694

Compositions and methods for predicting response to NaPi2b-targeted therapy

Mersana Therapeutics, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590171

Targeted replacement of endogenous T cell receptors

The Regents of the University of California · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566253

Targeted gene demethylation in plants

The Regents of the University of California · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11547759

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Montelino Therapeutics Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534495

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512110

Targeted delivery system and methods of use therefor

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512287

Targeted disruption of T cell and/or HLA receptors

Sangamo Therapeutics, Inc. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504394

Targeted ionophore-based metal delivery

The Regents of the University of California · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491145

Combination therapies comprising targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted